Clinical and histological patterns and treatment of pyoderma gangrenosum

被引:10
|
作者
Chakiri, Radia [1 ]
Baybay, Hanane [1 ]
El Hatimi, Asmae [1 ]
Gallouj, Salim [1 ]
Harmouch, Taoufiq [2 ]
Mernissi, Fatima Zohra [1 ]
机构
[1] Univ Hosp Hassan II, Dept Dermatol, Fes, Morocco
[2] Univ Hosp Hassan II, Dept Anatomopathol, Fes, Morocco
来源
关键词
Pyoderma gangrenosum; neutrophilic dermatosis; systemic disease; MANAGEMENT; COMORBIDITIES;
D O I
10.11604/pamj.2020.36.59.12329
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic dermatosis for which accurate epidemiological data are limited and therapy remains a challenge. The primary study's aim was to examine all cases of PG observed in our department over a 6-year period in order to describe the relevant characteristics and outcome under therapy. Fourteen patients were included (5 women, 9 men). The average age of our patients was 40,15 years. The classical, ulcerative form was found in 10 cases (71.42%), the pustular form in 4 cases (27.57%) and PG was multifocal in 4 cases. The PG was located preferentially to the lower limbs. Histological examination was realized in all patients and objectified inflammatory infiltrate composed of polymorphonuclear neutrophils in all cases with vasculitis in 4 cases. Six patients (42.85%) had associated disease at diagnosis of PG, including inflammatory bowel disease in two cases (14.28%), a blood disease in 2 cases (14.28%), lymph node tuberculosis and inflammatory arthritis in 1 case (7%). The most frequent first-line treatments were oral corticosteroids (7 cases) and other treatments used were colchicine in 2 cases, topical corticosteroids in 3 cases with good clinical evolution. Our study confirms that PG is a rare disease, associated in almost half of cases with systemic disease already present at diagnosis; in our Moroccan background, it is most often inflammatory bowel disease, hematological or solid cancer and tuberculosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Infliximab for the treatment of pyoderma gangrenosum
    Katy Cherry
    Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3 (6): : 301 - 301
  • [22] Diagnosis and treatment of pyoderma gangrenosum
    Brooklyn, Trevor
    Dunnill, Giles
    Probert, Chris
    BRITISH MEDICAL JOURNAL, 2006, 333 (7560): : 181 - 184
  • [23] Pyoderma gangrenosum: a treatment conundrum
    Lecamwasam, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (04) : E287 - E287
  • [24] Pyoderma Gangrenosum: Treatment Options
    Joachim Dissemond
    Angelo V. Marzano
    Philip J. Hampton
    Alex G. Ortega-Loayza
    Drugs, 2023, 83 (14) : 1255 - 1267
  • [25] Optimal Treatment of Pyoderma Gangrenosum
    Samuel L. Gettler
    Marti J. Rothe
    Caron Grin
    Jane M. Grant-Kels
    American Journal of Clinical Dermatology, 2003, 4 : 597 - 608
  • [26] Cyclosporine A for the treatment of pyoderma gangrenosum
    Rowe, WA
    GASTROENTEROLOGY, 1999, 116 (04) : A807 - A807
  • [27] Guselkumab for the treatment of pyoderma gangrenosum
    Sarsam, Sera
    Sexton, Holly
    Nicolopoulos, Jenny
    Dolianitis, Con
    JEADV CLINICAL PRACTICE, 2025, 4 (01): : 240 - 243
  • [28] Treatment of Pyoderma Gangrenosum With Vilobelimab
    Himed, Sonia
    Tawfik, Hoda
    Kaffenberger, Benjamin H.
    JAMA DERMATOLOGY, 2024, 160 (08) : 898 - 899
  • [29] Leukocytapheresis treatment for pyoderma gangrenosum
    Fujimoto, E
    Fujimoto, N
    Kuroda, K
    Tajima, S
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (05) : 1090 - 1092
  • [30] CLOFAZIMINE TREATMENT OF PYODERMA GANGRENOSUM
    KARK, EC
    DAVIS, BR
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1981, 5 (03) : 346 - 348